Enzymatica AB (SE:ENZY)

:ENZY

ENZY

Enzymatica AB

RESEARCH TOOLSreports

Want to see SE:ENZY full AI Analyst Report?

Enzymatica AB (ENZY) Price & Analysis

0 Followers

ENZY Stock Chart & Stats

kr2.00

-kr0.34(-10.43%)

At close: Mar 06 4:00 PM EST

kr2.00

-kr0.34(-10.43%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr3.40

Previous CloseN/A

Volume634.97K

Average Volume (3M)93.66K

Market Cap

kr611.69M

Enterprise Valuekr637.27M

Total Cash (Recent Filing)kr26.06M

Total Debt (Recent Filing)kr661.00K

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Jul 16, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding242,735,100

10 Day Avg. Volume44,136

30 Day Avg. Volume93,658

Financial Highlights & Ratios

PEG Ratio0.36

Price to Book (P/B)3.71

Price to Sales (P/S)8.56

P/FCF Ratio-11.19

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.3

Revenue Forecast (FY)kr109.00M

Bulls Say, Bears Say

Bulls Say

Diversified Commercialization ModelEnzymatica's mixed go-to-market (direct sales where it operates and partner/licensing agreements elsewhere) provides structural distribution flexibility. This model supports scalable geographic expansion, recurring supply/royalty revenue and lower single-market execution risk over the medium term.

Conservative LeverageA very low debt profile materially lowers refinancing and solvency pressures, giving the company forward optionality to absorb operational losses or raise growth capital without immediate solvency stress. This balance sheet conservatism is a durable buffer during multi-quarter recovery paths.

High Product-level Gross MarginA ~61% gross margin indicates strong product economics and potential pricing power for ColdZyme. If the company stabilizes sales and controls operating expenses, this margin allows for meaningful operating leverage and pathway to profitability without needing dramatic revenue increases.

Bears Say

Material Cash BurnSustained negative operating and free cash flow erode liquidity and force reliance on external funding or equity issuance. Over a 2-6 month horizon this constrains investments in marketing, inventory and partner support, raising execution risk unless losses narrow or financing is secured on favorable terms.

Deep Persistent Net LossesA near -96% net margin shows the business currently fails to cover operating costs at scale. Persistent heavy losses undermine shareholder value and limit capacity to reinvest in growth initiatives; reversing this trend requires sustained margin improvement or major operating changes.

Weak Revenue MomentumFlat and weakening revenue suggests limited organic demand expansion or channel execution issues. With high fixed costs relative to current sales, stagnant top-line undermines operating leverage and makes reaching breakeven more difficult absent new markets, product claims or materially better distribution performance.

ENZY FAQ

What was Enzymatica AB’s price range in the past 12 months?

Enzymatica AB lowest stock price was kr1.60 and its highest was kr3.40 in the past 12 months.

What is Enzymatica AB’s market cap?

Enzymatica AB’s market cap is kr611.69M.

When is Enzymatica AB’s upcoming earnings report date?

Enzymatica AB’s upcoming earnings report date is Jul 16, 2026 which is in 31 days.

How were Enzymatica AB’s earnings last quarter?

Enzymatica AB released its earnings results on Apr 28, 2026. The company reported -kr0.055 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.055.

Is Enzymatica AB overvalued?

According to Wall Street analysts Enzymatica AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enzymatica AB pay dividends?

Enzymatica AB does not currently pay dividends.

What is Enzymatica AB’s EPS estimate?

Enzymatica AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enzymatica AB have?

Enzymatica AB has 242,735,100 shares outstanding.

What happened to Enzymatica AB’s price movement after its last earnings report?

Enzymatica AB reported an EPS of -kr0.055 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.124%.

Which hedge fund is a major shareholder of Enzymatica AB?

Currently, no hedge funds are holding shares in SE:ENZY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enzymatica AB

Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help prevent and reduce the duration of the common cold. The company also produces various enzyme formulations. This mouth spray is distributed across several European markets under different brand names: ViruProtect in Denmark, STADAProtect in Germany, Psysiomer Stop Virus in France, and Zerinol Virus Defense in Italy.